scholarly journals Survival of Dental Implants in Oncology Patients versus Non-Oncology Patients: A 5-Year Retrospective Study

2020 ◽  
Vol 31 (6) ◽  
pp. 650-656
Author(s):  
Isadora França-Vieira da Silva ◽  
Carlos Omaña-Cepeda ◽  
Antonio Marí-Roig ◽  
José López-López ◽  
Enric Jané-Salas
Keyword(s):  
Success Rate ◽  
Cancer Patients ◽  
Dental Implants ◽  
Care Pathway ◽  
Oncology Patients ◽  
First Case ◽  
Osseointegrated Implants ◽  
Dental Hospital ◽  
History Of ◽  
The University

Abstract Patients with a history of cancer are increasingly common in the dental office. Treating cancer patients requires a multidisciplinary team, which should include the dentist, in order to control the complications that occur in the oral cavity and also to recover the patient undergoing treatment in any of its types: surgical, medical, radiotherapeutic, or its possible combinations. Dental implants can be a safe and predictable treatment option for prosthetic rehabilitation. The aim of this paper is to describe in retrospect the success rate of osseointegrated implants in oncology and non-oncology patients placed by the Master of Dentistry in Oncology and Immunocompromised Patients, as well as the Master of Medicine, Surgery and Oral Implantology of the University of Barcelona Dental Hospital, between July 2011 and March 2016. 466 patients were reviewed, with a total of 1405 implants placed, considering the oncological history of the patients and the implant success rate. The total success rate in the concerned period was 96.65%. When comparing cancer patients with healthy ones, the success rate has been 93.02% in the first case, and 97.16% in the latter. According to the literature review, our results encourage implant placement in cancer patients, it is important to recognize that this is an analysis of a complex care pathway with a large number of confounding variables. However, the findings should not be considered as generalizable.

The Humboldt-University and Its Rivals Under the Market Science Condition

2021 ◽  
pp. 41-46
Author(s):  
Ilya T. Kasavin ◽  
Keyword(s):  
Cultural Policy ◽  
Economic Competition ◽  
American Universities ◽  
Leading Role ◽  
Trading Zones ◽  
First Case ◽  
Humboldt University ◽  
History Of ◽  
Interdisciplinary Interaction ◽  
The University

In the modern rankings of higher education institutions almost monopolistic American universities (Harvard, Stanford, Princeton, etc.) play the leading role promoting the idea of the “entrepreneurial university”. The classic European university fails in the competition, and the idea of the Humboldt University is losing credibility. Our assumption is that this situation is in the large part due to the historical identity of civilizational missions, elites and forms of communica­tion (“trading zones”) that initiated these types of universities. The comparative history of European and American universities demonstrates that in the first case philosophers played a leading role in achieving the goals of cultural policy, and in the second, there were managers who won in the economic competition. European and American universities were, in different proportions, culture-forming centers and factors of economic development. University reforms were usually initiated from outside: these are its competitors and sponsors, politi­cians, and entrepreneurs. Who exactly takes on the functions of the moderator in the trading zones is a key question for the university’s fate. If a business model-oriented manager builds cooperation, then the university becomes the embodiment of academic capitalism. If a cultural policy is implemented in the interdisciplinary interaction of scientists themselves, then there is a chance to measure the university's development with humanistic values and the ethos of science.

scholarly journals Rare SARS-CoV-2 antibody development in cancer patients

2020 ◽  
Author(s):  
louisa hempel ◽  
Jakob Molnar ◽  
Sebastian Robert ◽  
julia veloso ◽  
Zeljka Trepotec ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Multiple Testing ◽  
Magnetic Beads ◽  
Vaccine Development ◽  
Rna Extraction ◽  
Humoral Response ◽  
Oncology Patients ◽  
Previous Hypothesis ◽  
Cast Doubt ◽  
History Of

Abstract SARS-CoV-2 antibody development and immunity will be crucial for the further course of the pandemic. Until now, it has been assumed that patients who were infected with SARS-CoV-2 develop antibodies as it is the case with other coronaviruses, like MERS-CoV and SARS-CoV. In the present study, we analyzed the antibody development of 77 oncology patients 26 days after positive RT-qPCR testing for SARS-CoV-2. RT-qPCR and anti-SARS-CoV2-antibody methods from BGI (MGIEasy Magnetic Beads Virus DNA/RNA Extraction Kit) and Roche (Elecsys Anti-SARS-CoV-2 immunoassay) were used, respectively, according to the manufacturers’ specifications.Surprisingly, in only 6 of 77 individuals with a confirmed history of COVID-19 antibody development was detected. Despite of multiple testing, the remaining patients did not show measurable antibody concentrations in subsequent tests. These results undermine the previous hypothesis that SARS-CoV-2 infections are regularly associated with antibody development and cast doubt on the provided immunity to COVID-19. Understanding the adaptive and humoral response to SARS-CoV-2 will play a key-roll in vaccine development and gaining further knowledge on the pathogenesis.

Influence of Bisphosphonates on Alveolar Bone Loss Around Osseointegrated Implants

2011 ◽  
Vol 37 (3) ◽  
pp. 335-346 ◽  
Author(s):  
Talal M Zahid ◽  
Bing-Yan Wang ◽  
Robert E Cohen
Keyword(s):  
Dental Implants ◽  
Alveolar Bone ◽  
Smoking Status ◽  
Estimating Equation ◽  
Implant Failure ◽  
Success Rates ◽  
Osseointegrated Implants ◽  
The University ◽  
The Relationship

Abstract The relationship between bisphosphonates (BP) and dental implant failure has not been fully elucidated. The purpose of this retrospective radiographic study was to examine whether patients who take BP are at greater risk of implant failure than patients not using those agents. Treatment records of 362 consecutively treated patients receiving endosseous dental implants were reviewed. The patient population consisted of 227 women and 135 men with a mean age of 56 years (range: 17–87 years), treated in the University at Buffalo Postgraduate Clinic from 1997–2008. Demographic information collected included age, gender, smoking status, as well as systemic conditions and medication use. Implant characteristics reviewed included system, date of placement, date of follow-up radiographs, surgical complications, number of exposed threads, and implant failure. The relationship between BP and implant failure was analyzed using generalized estimating equation (GEE) analysis. Twenty-six patients using BP received a total of 51 dental implants. Three implants failed, yielding success rates of 94.11% and 88.46% for the implant-based and subject-based analyses, respectively. Using the GEE statistical method we found a statistically significant (P  =  .001; OR  =  3.25) association between the use of BP and implant thread exposure. None of the other variables studied were statistically associated with implant failure or thread exposure. In conclusion, patients taking BP may be at higher risk for implant thread exposure.

Hemolytic transfusion reactions in oncology patients: experience in a large cancer center.

1984 ◽  
Vol 2 (5) ◽  
pp. 438-442 ◽  
Author(s):  
B Lichtiger ◽  
E Perry-Thornton
Keyword(s):  
Cancer Patients ◽  
Immune Status ◽  
Cancer Center ◽  
Intensive Chemotherapy ◽  
Oncology Patients ◽  
University Of Texas ◽  
Severity Of Disease ◽  
The University ◽  
Patients Experience ◽  
Transfusion Reactions

At The University of Texas M.D. Anderson Hospital and Tumor Institute at Houston, the incidence of hemolytic transfusion reactions over an eight-year period (1974-1981) was analyzed. Only four hemolytic transfusion reactions were reported out of 142,957 transfusions of blood (a frequency of one reaction in 35,739.25 transfusions). This could be due to the following factors: (1) Impairment of immune status related to the malignant process or temporary immunosuppression caused by intensive chemotherapy could enable patients to tolerate incompatible transfusions. (2) The reactions are overlooked or masked by the severity of disease in cancer patients in spite of an elaborate education for nurses, residents/fellows, and staff physicians about the dangers of hemolytic reactions. The figures herein reported are lower than those reported from non-oncology hospital settings.

scholarly journals Risk factors for bloodstream infections due to extended-spectrum β-lactamase producing Enterobacteriaceae in cancer patients

2018 ◽  
Vol 12 (04) ◽  
pp. 265-272 ◽  
Author(s):  
Sabahat Ceken ◽  
Gulsen Iskender ◽  
Habip Gedik ◽  
Fazilet Duygu ◽  
Duygu Mert ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cancer Patients ◽  
Bloodstream Infections ◽  
Antibiotic Use ◽  
Beta Lactamase ◽  
Oncology Patients ◽  
Extended Spectrum Beta Lactamase ◽  
Extended Spectrum ◽  
History Of ◽  
Independent Risk Factors

Introduction: Bloodstream infection (BSI) caused by Enterobacteriaceae is associated with mortality in cancer patients receiving chemotherapy. The aim of this study is to identify the risk factors and outcomes related to BSIs caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in cancer patients. Methodology: Hematology/oncology patients, who were diagnosed with BSIs caused by Enterobacteriaceae by positive blood cultures were evaluated retrospectively. Patients were divided into two groups by ESBL-positive and ESBL-negative Enterobacteriaceae bacteremia. Patients' demographic features, underlying conditions, comorbidity, neutrophil count, duration of neutropenia, antibiotic use in the previous three months before infection, mechanical ventilation, steroid use, central venous catheter implementation, total parenteral nutrition (TPN), hospitalization in the past three months, stay in intensive care unit, quinolone prophylaxis, and history of infection with ESBL-producing Enterobactericeae were evaluated. Risk factors related to BSIs caused by ESBL-producing Enterobacteriaceae and mortality were assessed. Results: A total of 122 patients were evaluated retrospectively. Quinolone propyhlaxis, TPN, infection with Extended Spectrum Beta-Lactamase positive ESBL-P Enterobacteriaceae during the previous three months, treatment with piperasillin-tazobactam or carbapenems in the previous three months were found to be independent risk factors for ESBL-P BSIs. Longer duration of neutropenia before BSI and complication at the beginning of BSI were found to be independent risk factors for mortality related to infection. Conclusions: ESBL-producing Enterobacteriacea should be treated with an appropriate antibiotic that is associated with better outcomes in hematology/oncology patients with BSIs. History of broad-spectrum antibiotic use and stay in hospital in the previous three months should be taken into consideration upon commencing antibiotic therapy.

VTE risk assessment in cancer

2016 ◽  
Vol 07 (01) ◽  
pp. 20-25
Author(s):  
I. Pabinger ◽  
C. Ay
Keyword(s):  
Risk Assessment ◽  
Cancer Patients ◽  
Medical Oncology ◽  
Clinical Importance ◽  
Cancer Surgery ◽  
Ambulatory Setting ◽  
Oncology Patients ◽  
Related Factors ◽  
Risk Assessment Models ◽  
Increased Risk

SummaryVenous thromboembolism (VTE) in patients with cancer is associated with an increased morbidity and mortality, and its prevention is of major clinical importance. However, the VTE rates in the cancer population vary between 0.5% - 20%, depending on cancer-, treatment- and patient-related factors. The most important contributors to VTE risk are the tumor entity, stage and certain anticancer treatments. Cancer surgery represents a strong risk factor for VTE, and medical oncology patients are at increased risk of developing VTE, especially when receiving chemotherapy or immunomodulatory drugs. Also biomarkers have been investigated for their usefulness to predict risk of VTE (e.g. elevated leukocyte and platelet counts, soluble P-selectin, D-dimer, etc.). In order to identify cancer patients at high risk of VTE and to improve risk stratification, risk assessment models have been developed, which contain both clinical parameters and biomarkers. While primary thromboprophylaxis with lowmolecular- weight-heparin (LMWH) is recommended postoperatively for a period of up to 4 weeks after major cancer surgery, the evidence is less clear for medical oncology patients. Thromboprophylaxis in hospitalized medical oncology patients is advocated, and is based on results of randomized controlled trials which evaluated the efficacy and safety of LMWH for prevention of VTE in hospitalized medically ill patients. In recent trials the benefit of primary thromboprophylaxis in cancer patients receiving chemotherapy in the ambulatory setting has been investigated. However, at the present stage primary thromboprophylaxis for prevention of VTE in these patients is still a matter of debate and cannot be recommended for all cancer outpatients.

How Valid are Patient Reports of Family History of Illness?

1980 ◽  
Vol 19 (03) ◽  
pp. 162-164 ◽  
Author(s):  
Rachel Harris ◽  
W. Margaret ◽  
Kathleen Hunter
Keyword(s):  
Family History ◽  
Medical History ◽  
Cancer Patients ◽  
Cause Of Death ◽  
Death Certificate ◽  
Recall Rate ◽  
Patient Reports ◽  
Small Subgroup ◽  
History Of ◽  
Medical Histories

The recall rate of patients’ family medical histories was studied in 200 cancer and non-cancer patients. Data on age and cause of death for parents and grandparents were collected. Although most patients knew the age and cause of death of parents, less than half knew for grandparents. Cancer patients had significantly greater recall for maternally related relatives. A subsample of patients’ family medical histories was compared to death certificate data. Patients’ reports were found to be highly inaccurate. Since only a small subgroup could provide medical history data for grandparents, the generaliz-ability for history of family illness is questioned.

Sign in / Sign up

Export Citation Format

Share Document